Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.06−0.17 (-2.73%)
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
Phathom Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Phathom Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -30.2%. For fiscal 2025 it was -126.3%, against -605.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -126.3% | +478.7 |
| FY2024 | Dec 31, 2024 | -605.1% | +28953.9 |
| FY2023 | Dec 31, 2023 | -29558.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -16.4% | +44.1 |
| Q2 FY2026 | Jun 30, 2026 | -23.7% | +168.2 |
| Q1 FY2026 | Mar 31, 2026 | -52.1% | +278.6 |
| Q4 FY2025 | Dec 31, 2025 | -36.7% | +214.3 |
| Q3 FY2025 | Sep 30, 2025 | -60.5% | +462.8 |
| Q2 FY2025 | Jun 30, 2025 | -191.9% | +1056.7 |
| Q1 FY2025 | Mar 31, 2025 | -330.7% | +4002.6 |
| Q4 FY2024 | Dec 31, 2024 | -251.0% | +11416.2 |
| Q3 FY2024 | Sep 30, 2024 | -523.3% | – |
| Q2 FY2024 | Jun 30, 2024 | -1248.6% | – |
| Q1 FY2024 | Mar 31, 2024 | -4333.3% | – |
| Q4 FY2023 | Dec 31, 2023 | -11667.2% | – |
See a number that looks wrong?